Autobio Diagnostics to invest idle funds for capital efficiency

Zhengzhou Autobio Diagnostics Co., Ltd. announced that its board of directors approved the use of idle funds for cash management. All 12 directors attended the meeting and unanimously passed resolutions for both idle raised funds and own funds management.

The company plans to invest up to 2.6 bn yuan of idle own funds, up to 1.4 bn yuan from public convertible bonds, and 15.4 bn yuan from non-public stock offerings. These funds will be allocated to low-risk, highly liquid financial products like structured deposits, large-denomination certificates of deposit, and wealth management products, with a maximum tenure of 12 months. This strategy aims to generate investment returns without impacting daily operations or fundraising project schedules.

The board has authorized the chairman or designated personnel to execute these investment decisions within a one-year timeframe, effective from the board's approval date. The company emphasizes that these measures will not alter the original purpose of the raised capital and are designed to benefit all shareholders.